Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 5/20 | 0.72 |
| ▸ | FNTB | P49356 | 5/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.70 |
| ▸ | MAPT | P10636 | 3/20 | 0.65 |
| ▸ | MEN1 | O00255 | 3/20 | 0.65 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | ATM | Q13315 | 1/20 | 0.63 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.61 |
| ▸ | SQLE | Q14534 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10750568 | 1.00 | FNTA (0.72) | FNTAFNTBKMT2AMAPTMEN1 | |
| SCHEMBL30173637 | 1.00 | FNTA (0.72) | FNTAFNTBKMT2AMAPTMEN1 | |
| SCHEMBL29595985 | 1.00 | FNTA (0.72) | FNTAFNTBKMT2AMAPTMEN1 | |
| SCHEMBL1395165 | 1.00 | FNTA (0.72) | FNTAFNTBKMT2AMAPTMEN1 | |
| SCHEMBL5080365 | 1.00 | FNTA (0.72) | FNTAFNTBKMT2AMAPTMEN1 | |
| SCHEMBL20435504 | 1.00 | FNTA (0.72) | FNTAFNTBKMT2AMAPTMEN1 | |
| SCHEMBL458220 | 1.00 | FNTA (0.72) | FNTAFNTBKMT2AMAPTMEN1 | |
| SCHEMBL1952603 | 1.00 | FNTA (0.72) | FNTAFNTBKMT2AMAPTMEN1 | |
| SCHEMBL31652308 | 1.00 | FNTA (0.72) | FNTAFNTBKMT2AMAPTMEN1 | |
| SCHEMBL458219 | 1.00 | FNTA (0.72) | FNTAFNTBKMT2AMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119876059-A | Biological catalytic synthesis method of ambrox | 天津大学浙江研究院(绍兴) | 2025-04-25 | — | — | CN | claimed |
| CN-107198683-B | A kind of farnesylacetic acid spiceleaf alcohol ester pharmaceutical composition and its preparation method and application | 上海慈瑞通鑫医药技术有限公司 | 2019-03-15 | — | — | CN | claimed |
| CN-107198683-A | A kind of farnesylacetic acid spiceleaf alcohol ester pharmaceutical composition and its production and use | 上海慈瑞通鑫医药技术有限公司 | 2017-09-26 | — | — | CN | claimed |
| CN-103012140-B | The preparation method of gefarnate | HUNAN FANGSHENG PHARMACEUTICAL CO.,LTD. (CN) | 2016-02-17 | — | — | CN | claimed |
| CN-103012140-A | Preparation method of gefarnate | HUNAN FANGSHENG PHARMACEUTICAL CO LTD | 2013-04-03 | — | — | CN | claimed |
| US-7015247-B2 | Ibuprofen-aspirin, hydroxymethylacylfulvene analogs and L-sugar illudin analogs | GUTTAG ALVIN | 2006-03-21 | — | — | US | claimed |
| CN-1228047-C | Remedies for heratoconjunctival diseases containing farnesyl acetate as the active ingredient | SANTEN PHARMACEUTICAL CO LTD (JP) | 2005-11-23 | — | — | CN | claimed |
| CN-1473039-A | Remedies for heratoconjunctival diseases containing farnesyl acetate as the active ingredient | ������ҩ��ʽ���� | 2004-02-04 | — | — | CN | claimed |
| US-20040014812-A1 | Remedies for keratoconjunctival diseases containing farnesyl acetate as the active ingredient | SANTEN PHARMACEUTICAL CO. LTD (JP) | 2004-01-22 | — | — | US | claimed |
| EP-1338279-A1 | REMEDIES FOR KERATOCONJUNCTIVAL DISEASES CONTAINING FARNESYL ACETATE AS THE ACTIVE INGREDIENT | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2003-08-27 | — | — | EP | claimed |
| US-20030008833-A1 | Ibuprofen-aspirin, hydroxymethylacylfulvene analogs and L-sugar illudin analogs | GUTTAG ALVIN (US) | 2003-01-09 | — | — | US | claimed |
| US-20020065254-A1 | Ibuprofen-aspirin and hydroxymethylacylfulvene analogs | GUTTAG ALVIN (US) | 2002-05-30 | — | — | US | claimed |
| US-4028385-A | RECTIFICATION | KURARAY CO., LTD. (JA) | 1977-06-07 | — | — | US | claimed |
| JP-52046018-A | — | — | None | — | — | JP | disclosed |
| JP-53103412-A | — | — | None | — | — | JP | disclosed |
| JP-53103412-A | — | — | None | — | — | JP | disclosed |
| US-4028385-A | RECTIFICATION | KURARAY CO., LTD. (JA) | 1977-06-07 | — | — | US | disclosed |
| US-4028385-A | RECTIFICATION | KURARAY CO., LTD. (JA) | 1977-06-07 | — | — | US | disclosed |
| US-4028385-A | RECTIFICATION | KURARAY CO., LTD. (JA) | 1977-06-07 | — | — | US | disclosed |
| JP-S5246018-A | PROCESS FOR PREPARATION OF FARNESYL ACETATES | SHIONO KORYO KK | 1977-04-12 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020065254-A1 | Ibuprofen-aspirin and hydroxymethylacylfulvene analogs | PTGES3, HPGDS, PTGES | FNTA 1248/4885FNTB 3061/4885KMT2A 1605/4885 |
| US-20040014812-A1 | Remedies for keratoconjunctival diseases containing farnesyl acetate as the active ingredient | MUC1, FUCA1, FUCA2 | FNTA 4/4885FNTB 36/4885KMT2A 2772/4885 |
| US-20030008833-A1 | Ibuprofen-aspirin, hydroxymethylacylfulvene analogs and L-sugar illudin analogs | GALE, TPT1, HPSE | FNTA 1214/4885FNTB 2716/4885KMT2A 842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.